Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Commercial Potential of Small-Molecule Kinase Inhibitors
- Mechanism/Structure/Discovery/Design.
- Protein Kinase Classification
- Protein Kinase Structure and Function
- Screening for Kinase Inhibitors
- Kinase Inhibitor Selectivity
- The Relative Importance of Selectivity
- Kinase Profiling
- Challenges in Kinase Inhibitor Development
- Influence of Mutations in the Target Kinase
- Acquired Drug Resistance
- p38α MAP Kinase Inhibitor Development
- Pharmacogenomics in Kinase Inhibitor Development
- Profiles in Innovation
- Astex Therapeutics
- SGX Pharmaceuticals
- Locus Pharmaceuticals
- Kinex Pharmaceuticals
- Ambit Biosciences
- Emiliem
- TargeGen
- Exelixis
- Outlook for Kinase Inhibitors
Tables
- 1. Global Sales of Marketed Kinase Inhibitors, 2006-2007
- 2. Orphan Designations for Gleevec in the United States
- 3. Select Kinase Inhibitors in Development
- 4. Select Kinases of Current Interest for Pharmaceutical Development
- 5. Companies Offering Kinase Profiling and Screening Services
- 6. Select Kinase-Based Deals
Figures
- 1. Growth in Global Sales of Herceptin, Gleevec, and Tarceva
- 2. X-Ray Crystal Structure of ATP Bound to Protein Kinase A
|
Related Report
|
View Cart
